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PGD reduces the need for abortion of a ‘mutation positive’ fetus 
– as was necessary prior to the development of PGD with use of 
prenatal (post-implantation) genetic testing through chorionic 
villus sampling or amniocentesis. Although also controversial, 
preimplantation genetic screening (PGS) for aneuploidy is also 
used in attempts to improve the success of IVF by eliminating 
embryos with abnormal chromosome numbers in women with 
repetitive failures at assisted reproduction and for women with 
habitual unexplained pregnancy loss. This discussion will 
focus on the former, more controversial use (i.e., PGD rather 
than PGS).
IVF use is rapidly increasing. Approximately 12% of women 
of childbearing age in the USA have used some form of 
assisted reproduction technology (Centers for Disease Control 
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Background: PGD and its 
applications
Over 2300 genes have now been identified for human disorders 
(National Center for Biotechnology Information 2008), all 
of which preimplantation genetic diagnosis (PGD) could 
potentially be used to identify. PGD, which requires IVF, is 
performed while the zygote is growing in the laboratory, with 
typically one cell of the early embryo (typically eight-cell 
stage) removed and tested genetically, prior to the embryo 
being transferred to the uterus. Embryonic biopsy is thought 
not to damage the embryo, and can therefore be implemented to 
help reduce the number of children born with genetic diseases 
or with a predisposition for disease (e.g., Huntington disease). 
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Abstract
Increasing use of preimplantation genetic diagnosis (PGD) poses numerous clinical, social, psychological, ethical, legal 
and policy dilemmas, many of which have received little attention. Patients and providers are now considering and using 
PGD for a widening array of genetic disorders, and patients may increasingly seek ‘designer babies.’ In the USA, although 
governmental oversight policies have been discussed, few specific guidelines exist. Hence, increasingly, patients and 
providers will face challenging ethical and policy questions of when and for whom to use PGD, and how it should be 
financed. These issues should be better clarified and addressed through collection of data concerning the current use of 
PGD in the USA, including factors involved in decision making about PGD use, as well as the education of the various 
communities that are, and should be, involved in its implementation. Improved understanding of these issues will ultimately 
enhance the development and implementation of future clinical guidelines and policies.
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US President’s Council on Bioethics and others (Vastag et al., 
2004a). However, as of yet, few specific guidelines exist and no 
policy has been implemented.
Existing data on PGD decision 
making and practices
With regard to the conduct of IVF, few studies of patients’ and 
providers’ views and decision making have been conducted. 
Moreover, most of these studies have been conducted outside 
the USA, where national healthcare systems differ significantly 
from those in the USA, particularly with respect to insurance 
coverage and access to services. Assisted reproduction treatment 
providers have been surveyed concerning attitudes and practices 
in several areas related to IVF; but clinical decision making 
concerning PGD remains unexamined. It is not known, for 
example, whether, when, and to whom clinicians in the USA 
offer PGD, and how these providers decide which genetic tests 
to offer for PGD.
Overall, public attitudes appear to remain mixed, and are 
affected by factual questions such as whether embryos would 
be destroyed and the nature of the trait or disease being tested 
for, and by general cultural attitudes (Kalfoglou et al., 2005a). 
In Germany, attitudes about PGD are divided and may reflect 
wariness of eugenics as a result of Nazi practices (Meister et 
al., 2002). In Italy, the strong influence of the Catholic Church 
has led to an outright ban on the practice of PGD (Robertson, 
2004). A few studies of patients who have undergone PGD have 
been conducted, but again, mostly in other countries. PGD has 
been viewed favourably by IVF patients in Australia, the UK 
and Spain, although 41% found the process involved of IVF/
PGD to be ‘extremely stressful’. However, these rates of stress 
were somewhat comparable to those of conventional prenatal 
diagnoses (Katz et al., 2002; Lavery et al., 2002; Snowdon and 
Green, 1997). Notably, IVF is covered to varying degrees by 
national healthcare policies in Australia, France, Germany and 
the UK (Jain and Hornstein, 2003), decreasing the financial 
hardships imposed on patients. In Australia, of parents who had 
children conceived with IVF, 26% expressed concerns about 
their child’s future health and vulnerability (McMahon et al., 
1997; Gibson et al., 2000). Interest in utilizing PGD increased 
among patients at risk for thalassaemia in Sicily if they had 
previously undergone prenatal diagnosis and abortion of an 
affected fetus (Chamayou et al., 1998), and in Hong Kong if 
couples had an affected child or a fertility problem (Hui et al., 
2002). Attitudes of infertile women in the USA towards gender 
selection for social reasons, but not other aspects of PGD, have 
also been probed. Of these women, 40.8%, would want to select 
gender if no added cost were involved (Jain et al., 2005). In US 
interviews with a small number of patients who had utilized 
PGD, as well as with several patients who were at risk but 
did not use it, and with a variety of healthcare professionals, 
respondents described several perceived advantages and 
disadvantages of using PGD (Kalfoglou et al., 2005b).
People at risk for Huntington’s disease - a fatal, incurable, adult 
onset, neurodegenerative disease -  struggle with reproductive 
decisions and weighing competing issues (Klitzman et al., 
2007a). They commonly consider PGD, but often remain 
wary, given the costs, the relative ‘newness’ of, and hence lack 
of familiarity with, the procedure, and moral qualms about 
and Prevention [CDC], 2003), and approximately 1% of 
all births currently result from IVF therapies (CDC, 2007). 
In 2005, over 52,041 infants were born in the USA using 
assisted reproduction treatment (CDC, 2005a), 99% of which 
now involves conventional, non-surgical IVF (CDC, 2005b). 
Increasingly, couples who elect to utilize IVF to conceive 
may ask to consider adding PGD to test for genetic mutations 
associated with medical conditions or to identify an embryo’s 
gender for strictly social, not medical, reasons (Klitzman et al., 
2008).
Originally, PGD was used to select against embryos carrying 
mutations for severely disabling and usually lethal monogenic 
conditions that had complete penetrance and often paediatric 
onset (e.g., Tay Sachs disease, cystic fibrosis, and spinal 
muscular atrophy). But patients and providers are now 
considering and using PGD for a widening array of genetic 
disorders of increasing age of onset, decreased penetrance 
and increasing genetic complexity, for which prevention or 
treatment may in fact be available – including hereditary breast/
ovarian cancer susceptibility, familial adenomatous polyposis 
and type 1 diabetes (Offit et al., 2006).
In addition, recently, with the explosion of genome-wide 
association research, studies have identified genetic variants 
that increase susceptibility to common disorders such as 
obesity, diabetes, myocardial infarction, inflammatory bowel 
disease, macular degeneration, psychiatric illness and many 
types of cancer (Topol et al., 2006; Baum et al., 2007; Easton 
et al., 2007; Frayling, 2007; Swaroop et al., 2007; Tremelling 
and Parkes, 2007). The relative risk for most of these variants is 
modest, generally ranging from 1.1 to 1.5. Currently, however, 
risk stratification, although one of the ultimate goals of future 
genetic research, has shown little clinical utility. Many of these 
discoveries have been reported in the media (Topol et al., 2006; 
Baum et al., 2007; Easton et al., 2007; Frayling, 2007; Swaroop 
et al., 2007; Tremelling and Parkes, 2007). These reports may 
confuse patients who may, along with providers, then seek to 
avoid transmission of these low-penetrance polymorphisms or 
low-risk alleles.
Questions remain concerning long-term risks of IVF and 
PGD to mother and child. There may be increased cancer 
risk to mothers from the hormone treatments associated with 
IVF, especially for those women carrying inherited cancer 
susceptibility genes (Salhab et al., 2005; Lerner-Geva et al., 
2006). IVF has been associated with an increased incidence of 
low birthweight babies, preterm deliveries, multiple gestation 
and birth defects (Kovacs, 2002; Olson et al., 2005; Wright et 
al., 2007). Although rare, IVF may heighten the risk of genetic 
imprinting disorders such as Beckwith-Wiedemann syndrome 
(Gosden et al., 2003). Evidence is also emerging of long-term 
effects of IVF on growth and body composition in children 
conceived with IVF (Ceelen et al., 2007; Miles et al., 2007). 
The first IVF baby was born only 30 years ago in 1978 (Steptoe 
and Edwards, 1978), and the first use of PGD followed 10 
years later (Handyside et al., 1989). Hence, at present, to assess 
fully the long-term effects of these procedures on offspring is 
impossible. PGD has been tightly regulated (and in some cases 
even banned) in several European countries, but remains largely 
unregulated in the USA (ESHRE, 2007). The imposition of 
possible federal and state guidelines, combined with stringent 
professional society self-regulation, has been discussed by the 
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or other potentially pertinent medical history of the mother, 
other sociodemographics of the parents besides age (such as 
ethnicity and religion), and the inter-relationships between 
these and several other variables (e.g., PGD success rates).
Moreover, numerous questions persist as to how exactly 
clinicians and patients view and make decisions about the use 
of PGD, and weigh the pros and cons; and which challenges 
and barriers exist to optimal use and to avoidance of possible 
misuse of this technology. For example, not all patients at risk 
who visit an IVF clinic may end up opting for PGD. Data 
suggest a wide range of parents’ attitudes concerning views of 
the disorder that they or their family may have or are at risk 
of having (Klitzman et al., 2007a). Providers in areas other 
than IVF (e.g., obstetrics, paediatrics and genetics) may also 
consult with patients, and present PGD and other reproductive 
options in ways that can shape patients’ decisions to use PGD. 
Thus these other providers’ views and practices are crucial to 
examine as well.
Specific ethical and policy 
challenges associated with PGD 
use
Providers now treat patients who want to bear children who 
lack   mutations associated with conditions for which these 
patients are at risk. In the near future, couples may seek not 
only to avoid mutations associated with Tay Sachs or cystic 
fibrosis, as at present, but actively pursue having ‘designer 
babies’. As a result, in the context of a relative lack of data 
about current practice and attitudes, PGD presents a series of 
ethical and policy dilemmas, as summarized in Table 1 and 
described below. To help address these dilemmas, several 
specific areas of research are needed. Data on practices 
cannot solve normative questions of how decisions should 
be made, but can nonetheless inform and enhance policy 
making, illuminating specific types of problems that policies 
should address with appropriate nuance to arrive at optimal 
solutions.
How often is PGD requested and/or 
performed and why?
A starting point for consideration of PGD regulation is an 
understanding of current patterns of PGD practice. Data are 
vital regarding the conditions for and the frequencies with 
which PGD is used: for example, data on requests by patients, 
procedures clinics have provided, been unable to perform or 
declined to provide; and error rates, as determined by prenatal 
or postnatal confirmatory testing, given that PGD is imperfect 
and currently associated with a 2–3.5% chance of misdiagnosis 
(Findlay et al., 1996; ESHRE PGD Consortium Steering 
Committee, 2000). Questions emerge as to what kinds of 
oversight, if any, are needed for laboratories performing PGD 
to ensure high test accuracy, and whether unique laboratory 
regulatory problems arise with PGD. Information is needed 
on rates of successful delivery of a child per cycle of IVF with 
PGD, and the medical outcomes of children conceived with 
IVF/PGD, including the frequencies of prematurity, low birth 
weight, birth defects and developmental delays.
interfering with what ultimately is ‘in God’s hands’. Patients 
often feel uncomfortable rejecting a ‘mutation positive’ fetus. 
Frequently, healthcare providers and other family members 
have strong opinions about what an at-risk individual should 
do regarding PGD. Especially with regard to an autosomal 
dominant condition where unilateral transmission is possible, 
members of a couple may disagree, significantly stressing a 
relationship (Klitzman et al., 2007b).
Need for additional data collection 
and research
Increasingly, practitioners and patients will face ethical and 
policy questions of when to use PGD. Therefore, in hopes 
of better informing providers and patients and optimizing 
policy-making, further targeted research is needed in several 
areas. The European Society of Human Reproduction and 
Embryology (ESHRE) consortium has published data on 
PGD use from 45 centres (ESHRE PGD Consortium Steering 
Committee, 1999, 2000, 2007) e.g., on numbers of cycles, 
methods used, outcomes, mean female age, and number of 
embryos diagnosed. Currently, US clinics are mandated by 
law to provide information from their respective centres to 
the CDC annually on the number of initiated IVF cycles and 
the percentage of successful births that result. However, in 
the USA, no data are yet available in several areas, including 
long-term follow-up of children conceived with IVF or PGD 
(Vastag et al., 2004a). Recently, there have been a few efforts to 
collect quantitative data on rates at which IVF clinics perform 
PGD (Genetics and Public Policy Center of Johns Hopkins 
University and Princeton Survey Research Associates, 2002; 
Baruch et al., 2006). More systematic data collection about 
PGD implementation is also being planned, with the National 
Institute of Health (NIH) recently soliciting proposals to follow 
outcomes of children conceived via IVF (National Institute 
of Child Health and Human Development, 2007). However, 
what data will in fact be collected, and to what degree 
private clinics will agree to provide such information – with 
what level of detail or follow-up – has yet to be determined. 
Many providers may not wish to disclose such data publicly, 
although to do so may ultimately be in the best interests of 
furthering public health. Indeed, less than half of US assisted 
reproduction clinics responded to one recent study of PGD 
practices (Baruch et al., 2006), hence suggesting the possible 
need for more required, rather than purely voluntary data 
reporting. The relatively more comprehensive data collection 
system of ESHRE provides an important possible model for 
data collection in the USA, offering important information 
about risks involved. Although one might argue that if data 
are collected in Europe, they do not need to be collected in 
the USA, healthcare systems, various health indices,  and 
population sociodemographics in fact vary between Europe 
and the USA (World Health Organization) in ways that may 
affect PGD use and outcomes.
In the USA, many gaps remain in the knowledge of PGD use: 
when exactly and for whom it is or is not chosen (i.e., in terms 
of sociodemographics); for which conditions; and which other 
types of factors (e.g., insurance coverage, other maternal 
diagnoses) shape patients’, PGD providers’ and physicians’ 
decisions. In Europe, published reports have not yet examined 
several additional factors, e.g., prior obstetric (if relevant) 
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For which indications?
Several connected questions arise about the indications for which 
PGD should be used, posing a range of issues related at times to 
genetic enhancement of future generations: should parents have 
the right to choose, and thus ‘improve’ in any way they wish 
the genetics of their yet unborn children? Dilemmas emerge of 
how to weigh patients’ autonomy against possible psychological 
risks to the child and social risks.
Difficult questions arise related to both genetics and psychosocial 
issues, regarding the indications for PGD. If PGD is used to 
eliminate or reduce risks from cancers that have adult onset, 
where should the line be drawn with regard to the penetrance for 
cancer susceptibility alleles (e.g., 80%, 50% or 30%)? PGD could 
be used for polygenic diseases (e.g., type 1 diabetes) for which 
the absolute risk of having an affected child is low. Tensions 
then exist between preventing a disease in a child that may not 
occur for 50 years, if ever, versus posing possible medical risks 
to the mother now through the IVF/PGD procedure. Moreover, 
if, as is the case today in the USA, health insurance often does 
not cover PGD, and PGD is thus not universally affordable, 
only higher income people will be able to eliminate certain 
adult-onset or low penetrance genetic diseases, while the poor 
will not, thus furthering health inequities. At the same time, 
of note, microarrays may offer increased selective potential, 
theoretically allowing parents using PGS to choose the best 
of several embryos, based on much more information than is 
currently available (Sermon et al., 2004).
Some individuals may see patient autonomy as guaranteeing 
the right to undergo PGD, as long as the patient can afford it, 
for predispositions to any medical condition for which a genetic 
basis has been identified. Yet such individual autonomy needs 
to be weighed against potential social costs and injustices. 
Specifically, since many of these uses of PGD may well be 
available only to the wealthy who can afford them, certain 
disorders may be reduced or eliminated among higher but not 
lower socioeconomic groups, and patients with the disease, 
whose parents did not undergo PGD, may face added stigma 
and less political support for social or reduced benefits. Data on 
views of these issues among the general public, patients at risk 
for transmitting hereditary susceptibility, and providers would 
be helpful in stimulating public discussion and examining and 
addressing these concerns.
Should certain genetic traits be positively 
selected for?
Conversely, questions surface concerning positive selection 
for certain genetic traits. For example, parents who are deaf 
(McLellan, 2002) or have achondroplasia (Parens and Asch, 
2003) may want to have a similarly affected child. Indeed, 3% 
of directors of assisted treatment have positively selected for 
a disability in an embryo (Keye and Bradshaw, 2004). Here, 
patients’ desires and autonomy may need to be weighed against 
possible social or even medical harm that their yet unborn child 
may face as a result of the decision to produce a child who shares 
these traits. Although limited data exist, the media have given 
attention to positive selection (McLellan, 2002). But, how often, 
when and why such anecdotal practices in fact occur remains 
unknown, and should be investigated in order to inform policy 
and practice.
Table 1. Specific ethical and policy challenges associated with issues concerning preimplantation genetic 
diagnosis (PGD) use.
How often is PGD requested and/or performed and why?
For which genetic indications?
  For which conditions should PGD be performed?
  Should certain traits be positively selected for?
  Should human leukocyte antigen matching be used for future tissue donation?
  Should gender selection be used for non-medical reasons?
  Should other ‘social traits’ be selected for or against?
For which parents
  Should PGD be offered to patients who have or may develop a serious illness?
  Should PGD be provided to women above a certain age?
  Should patients be refused PGD because of psychosocial criteria? and if so, when?
Provider issues
  How much latitude should PGD providers be allowed?
  What exactly are and should patients be told about PGD risks and benefits?
  What training/knowledge about PGD should physicians more broadly have?
  Do physicians have a ‘duty to inform’?
Other issues
  Should insurance companies cover PGD, and if so, how much?
  What should children born using PGD be told, and when?
  How will issues concerning PGD change over time?
  Should more state or federal regulation be implemented?
  How exactly should public and professional education about PGD be most effectively enhanced?
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Should other social traits be selected for?
Sex selection raises additional concerns about a slippery 
slope – whether other social traits might also be selected for 
or against. For example, when genes associated with height, 
intelligence, athleticism, violence, sexual orientation, skin 
colour or a range of other non-disease traits are identified, 
these, too, could be targets for selection. Indeed, a recent 
US study found that 9% of PGD was performed for non-
medical reasons (Baruch et al., 2006). The study did not 
define or specify to what this term refers, although at present 
it presumably connotes sex selection for non-medical reasons. 
Selecting against embryos on the bases of such non-medical 
traits raises fears of possible eugenics in the future (Charuvstra 
et al., 2002; Vastag et al., 2004b). PGD may then begin to alter 
broader social attitudes towards traits and diseases that can 
be selected against. Increasingly, many Americans, especially 
as they are having fewer children (Popenoe, 1993), may 
desire for themselves, and believe that others should desire, 
‘a perfect baby’. Research similar to that suggested above 
on non-medical sex selection would be helpful here as well. 
These questions of the conditions for which PGD should be 
performed raise quandaries that providers and policy makers 
should address and consider with caution and sensitivity, 
particularly with regard to groups who may already face stigma 
or vulnerabilities. These questions pose profound challenges 
too, given possible political concerns about such efforts. 
For which parents?
Should PGD be offered to patients who have or may 
develop a serious illness?
Challenging questions emerge, too, as to whether an adult 
patient who has or may develop serious illness (e.g., 
Huntington’s disease) should undergo PGD, knowing that he 
or she is unlikely to be able to rear the child beyond a certain 
point (Towner and Loewy, 2004). Patient autonomy suggests 
patients have the right to have a child in such situations, but it 
could be argued that to create the pregnancy though PGD may 
not be in the best interests of the yet unborn child, and may 
raise broader social concerns. Currently, a clinician may assist 
parents in many ways in having a child regardless of their 
underlying medical conditions. For example, obstetricians 
may care for pregnant women with drug abuse or other 
problems that may endanger the fetus or impair their abilities 
to act as parents. Assisted reproduction treatment may be used 
with parents who have other medical problems – for example, 
men with cystic fibrosis, women with Turner syndrome, 
and patients with cancer to harvest eggs or sperm prior to 
chemotherapy for use after cancer treatment. However, PGD 
involves a more direct and invasive medical intervention in 
achieving the pregnancy. Hence, the ethical calculus may shift. 
The degree to which resources are now used for this purpose 
is not clear and may be limited. Yet to gauge the frequency 
of this practice, and thus the magnitude of the problem, it is 
important to establish mechanisms for on-going  monitoring 
of patterns of PGD use over time, which can inform decisions 
of how involved policy makers should be in this arena.
Should HLA matching be used for future 
tissue donation?
Controversy arises, too, about human leukocyte antigen 
(HLA) matching to enable future tissue donation from an 
unaffected infant who is not yet born to a living affected child. 
Parents can thereby be creating a new child to donate tissue, 
regardless of that child’s eventual feelings and preferences. 
The new child would in effect be conceived and used in part 
as a means to an end – to provide tissue for a sibling (Fasth 
and Wahlstrom, 2004; Fost, 2004; Verlinsky et al., 2004; 
Damewood, 2006). Providers have opted to use PGD for this 
purpose, depending on various parameters such as the severity 
of and availability of alternative treatments for the existing 
child’s disease, and perhaps even the age of the mother. Yet 
ethical questions have been raised (e.g., concerning the fate of 
unused embryos) that can and should be discussed in patient 
counselling (Kahraman et al., 2007). Cultural factors may 
affect these decisions: for instance, in Turkey and perhaps 
elsewhere, couples cannot freeze embryos for future use 
(Kahraman et al., 2007). Additional research is thus needed 
to quantify how often PGD is requested and/or used for such 
HLA typing, with what parameters (e.g., in terms of types and 
severities of disease, age of affected child, age of mother), and 
how providers and potential patients decide whether and when 
to use PGD for this purpose.
Should gender selection be used for non-
medical reasons?
Gender selection for non-medical reasons (e.g., ‘family 
balancing’) also generates controversy (Charuvstra et al., 
2002; Vastag et al., 2004b). For US couples undergoing 
fertility treatment, 40% report that they would like to select 
the sex of their baby (Jain et al., 2005). Of assisted treatment 
directors, 42% would provide PGD for such non-medical 
gender selection (Baruch et al., 2006). Yet when, if ever, 
such selection does or should occur is not clear. Critics may 
argue that gender selection for non-medical reasons should be 
banned, but all such cases may not be equally problematic. For 
example, a couple that has had four daughters and now wants 
a son for family balancing, when the wife is 38 years old and 
hence nearing the end of her natural reproductive years, may 
not be as ethically problematic as a young couple wanting 
only one child and wanting it to be a boy, or a couple desiring 
a particular gender-linked birth order for their children. It is 
not clear whether more widespread gender selection would 
alter the demographics of gender ratios in the USA as it has in 
India or China (Hesketh and Xing, 2006). Also, it is unclear 
what the impact would be on smaller families or whether 
family size would become more homogenized and, if so, 
what the social effects would be: i.e., whether devaluation of 
one gender would increase because children of the ‘correct 
gender’ would be seen as more desirable. Further data, based 
on surveys, on the extent to which potential parents may opt 
for sex selection, the motivations for such selections, and 
the likely impact on broader gender distribution would be 
helpful here. In addition, considerations should be given to 
the possibility of developing guidelines to assist providers in 
clarifying and deciding when, if ever, gender selection may be 
more or less ethically possible or problematic.
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Provider issues
How much latitude should PGD providers 
be allowed?
Although certain providers may resist use of PGD due to 
these ethical and moral quandaries, others may feel more 
comfortable using PGD. Patients, too, no doubt vary in these 
decisions. Providers’ and patients’ religion, gender, age, past 
reproductive experiences, psychological state, concerns about 
a particular condition and genetic understanding may play 
critical roles here. Medical knowledge about PGD may also 
shift over time. Whether, when, and how often providers’ 
own moral concerns affect their recommendations about 
PGD is not clear. Particular providers may or may not refer 
patients for, or perform, PGD for particular indications for 
technical or moral reasons. Such data would be useful to 
have in approaching possible policy formulation regarding 
this issue. Policy makers face questions of whether to address 
the amount of latitude that providers now exercise in being 
able to choose or reject patients for PGD. Some providers 
may feel that they have autonomy to make such decisions, 
despite potential countervailing claims of social injustice. 
Surveys of providers’ attitudes and practices can help frame 
understandings of the nature and scope of potential problems 
in this area, and inform providers’ and policy makers’ possible 
approaches towards these issues.
What exactly is and should be said to 
patients about PGD risks and benefits?
Dilemmas arise, too, concerning what information should be 
provided to patients as part of appropriate counselling and 
informed consent for PGD. Informed consent practices for 
PGD have been examined in 11 other countries, although not 
the USA, and have been found to vary greatly. While some 
countries mandate pre- and post-counselling, others simply 
require offering patients the choice of such services (Knoppers 
and Isasi, 2004). In US clinics, informed consent for genetic 
testing, including PGD, is required. The New York State 
Department of Health (1998) specifies the information content 
for consents for genetic tests for all laboratories providing PGD 
to patients receiving care in New York, although this stipulation 
covers only the genetic testing involved in PDG and not certain 
other processes involved (e.g., specifics of informed consent 
content for biopsying embryos).
What patients are and should be told about PGD and the risks 
and benefits involved is uncertain. Anecdotally, many patients 
expect to become pregnant on the first IVF cycle, yet with each 
cycle, the ‘take-home-baby rate’ may be as low as 20% for women 
over 35 years of age (Harper et al., 2006). Recently, one study 
reported that PGS may in fact decrease the rate of pregnancies 
and live births in women 35–41 years old (Mastenbroek et 
al. 2007), although these findings have been criticized due to 
questions of patient selection and poor techniques involved 
(Cohen and Grifo, 2007; Munné et al., 2007). Usually, PGD 
results are accurate; but false positives and negatives have 
occurred (Gosden et al., 2003). Given the newness of PGD, and 
lack of data about outcomes of children conceived with PGD 
Should PGD be provided to women above a certain 
age?
Clinicians face specific dilemmas, too, of whether to provide 
PGD to women beyond a certain age, given possible increased 
risks to both the mother and child, as well as questions about the 
ability of older parents to rear the child through adolescence. 
Potentially, guidelines could be developed concerning the 
maximum age of mothers, to help PGD providers clarify the 
pros and cons to women (e.g., in their late forties or fifties) 
undergoing the procedure. Further research here could help 
assess physiological and psychological risks to the parents 
and the child. Guidelines need not prohibit use of PGD 
beyond a particular maternal age, but could aid clinicians 
(e.g., in weighing competing parameters and concerns) to 
determine how to decide whether to offer the procedure to 
particular women, and assist would-be parents in deciding 
whether to pursue the technique.
Should patients be refused PGD because of 
psychosocial criteria? And if so, when?
Providers may also be using other sociodemographic or 
psychosocial criteria in deciding whether to offer PGD to 
particular patients. For example, in screening for assisted 
reproduction treatment, though not PGD per se, providers 
have indicated that they would be very or extremely likely 
to turn away those from certain sociodemographic groups: 
human immunodeficiency virus-infected women (59%), gay 
couples (48%), and couples on welfare (38%) (Gurmankin 
et al., 2005). In part, IVF providers wish to have the highest 
possible ‘take home baby’ success rates, as these statistics 
are reported annually to the CDC and available publicly on 
the internet. Hence, PGD providers may not accept patients 
who, they believe, face psychosocial challenges (e.g., 
based on socioeconomic status, single parenthood or sexual 
orientation) because these providers fear these factors may 
lower overall success rates. Potentially, IVF providers may 
extend such selection biases to the use of PGD. A range 
of other factors and circumstances may also affect PGD 
provider decisions – e.g., patients’ medical and psychological 
histories, risks of multiple gestations, unknown risks of IVF 
and PGD (i.e., increased risks of obstetric and perinatal 
complications, including perinatal mortality, preterm 
delivery, low birthweight, birth defects and imprinting 
disorders), and potential psychological effects on a couple 
(e.g., if the members of the couple differ in preferences and/
or  expectations).
As examined further below, dilemmas thus surface in weighing 
patients’ autonomy against both providers’ autonomy and 
judgment on the one hand, and social justice (i.e., equal 
access to treatment) on the other. Studies are needed about 
when and how often providers in fact refuse to offer PGD 
to patients based on these varying grounds and how much 
providers differ in these decisions.
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the insurers provide coverage. Some states exempt businesses 
with relatively small numbers of employees from having to 
provide any coverage to employees. Moreover, whether any 
states mandate coverage of PGD is unclear (Reynolds et al., 
2003; ASRM, 2007), and many individuals cannot afford to 
pay the additional out-of-pocket expenses. Insurers may also 
deny coverage on varying grounds (e.g., related to the condition 
being tested for or the age of mother). Anecdotally, if a woman 
previously underwent an abortion following a confirmed 
prenatal diagnosis (e.g., through amniocentesis or chorionic 
villus sampling), an insurance company may opt not to cover 
PGD in the future, but to rely instead on the couple’s willingness 
to terminate an affected fetus, which is less expensive. IVF is 
often covered only for couples with infertility and not for risks 
of certain mutations in offspring. Data on current patterns and 
indicators of insurance coverage would be valuable to elucidate 
in which areas policy interventions need to be considered. Such 
data could gauge the number of requests for insurance that 
are covered, and the absolute amount and proportions of costs 
covered – both for beneficial public health indications such as 
preventing fatal, fully penetrant disorders and for elective uses 
such as gender selection for non-medical reasons.
Identification of successful strategies with insurance companies 
could also aid other providers and patients, particularly as PGD 
use spreads. Unequal insurance coverage is hardly unique to 
PGD, and reflects larger systemic problems. Still, differences 
in insurance coverage for PGD have particular long-term social 
implications, given the potential for differential application of a 
new eugenics associated with   socioeconomic status.
What should be told to children born 
using PGD, and when?
Subsequent dilemmas arise concerning whether, when, and 
what children conceived using PGD should eventually be told 
about the fact that PGD was utilized. Such information could 
potentially affect these children’s self-image, but may also have 
positive practical consequences should later problems due to 
PGD use be identified. Research on public attitudes and views 
of child development experts can be helpful here.
How will issues concerning PGD change 
over time?
As tests for additional genetic susceptibilities are employed 
using PGD and successes or problems surely occur, PGD will 
no doubt receive increased attention. Providers’ and patients’ 
experiences will certainly continue to evolve over time. 
Ongoing research will be needed to assess these new trends and 
challenges.
Should more US state or federal 
regulation be implemented?
Data on provider and patient practices cannot solve normative 
questions of how decisions should be made, but can nonetheless 
inform and enhance policy making, illuminating specific types 
of problems that policies should address with appropriate 
nuance in order to arrive at appropriate solutions. The 
(e.g., effects on embryos that may only become obvious later in 
life), and patient and provider understanding of PGD risks and 
benefits, research is needed on how much information patients 
are given and comprehend about PGD limitations and potential 
complications. Subsequent research is needed to define which 
benefits and risks of IVF and PGD should be discussed, and 
how this information is and should best be presented.
What training regarding PGD should non-
PGD providers receive?
Research has not been conducted on whether genetic counsellors 
and other healthcare providers who may confront questions 
about PGD (e.g., in obstetrics, paediatrics, neurology and 
oncology) are sufficiently or optimally trained, knowledgeable 
about or comfortable in discussing PGD and what kinds of 
targeted professional educational efforts may be needed.
Do physicians have a duty to inform?
Questions emerge, too, of whether physicians have a duty to 
inform, i.e., to tell all patients at risk of having a child with 
a genetic condition of the availability of PGD to prevent 
‘wrongful birth’ of an affected child. Clinicians may decide to 
inform patients about PGD as an option, although it remains 
prohibitively expensive for many patients. The financial 
limitations on the accessibility of this procedure may lead many 
parents to feel guilty and perhaps later face rebuke by others 
for not having somehow used this technology. Knowledge 
about what patients would want to be told about PGD may 
help identify the proper scope of information to be provided, 
especially in jurisdictions that use a ‘reasonable patient’ standard 
of disclosure for informed consent. Here again, desires to allow 
providers and relevant professional organizations latitude to 
determine their own approaches to PGD can potentially clash 
with broader societal public health interests. Policy makers 
should consider enhancing understanding, and potentially 
addressing these issues.
Other issues
Should insurance companies cover PGD? 
And if so, how much?
Importantly, cost issues require further examination as well. The 
extent to which insurance companies should pay for PGD remains 
unclear. Without coverage, financial barriers are considerable, 
since fees for IVF are typically US$10,000–15,000 per cycle 
and using PGD costs an additional US$2,500–6,000 (Simpson 
et al., 2005). Moreover, couples often require more than one 
cycle. Approximately 16 states mandate coverage of infertility 
services by insurance companies to some degree, but range 
widely in whether and to what extent they cover IVF per se 
(Reynolds et al., 2003; ASRM, 2007). Of these states, mandates 
in four include only IVF coverage, five include IVF as well as 
certain other infertility services and two include diagnosis and 
treatment of infertility but exclude IVF coverage. States vary 
in the length of time that patients must be ‘infertile’ to meet 
criteria to receive coverage. Two states require only that insurers 
inform employers that IVF is available, but do not require that 
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to enhance public and professional comprehension of these 
issues, and policy makers should consider ways of supporting 
such critical endeavours. The research and educational agendas 
outlined above can be enormously important in achieving these 
goals.
‘How beauteous mankind is!’ Miranda, in Shakespeare’s 
Tempest, optimistically exclaims, ‘O brave new world, that has 
such people in it!’ Aldous Huxley borrowed part of her dialogue, 
using it ironically in the title of his prescient 1932 novel, Brave 
New World. The reality may lie somewhere between Miranda’s 
hope and Huxley’s fear, depending on how physicians, medical 
educators, policy makers, patients and the public now respond.
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